Traws Pharma, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was $0.00.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $0.00.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $7.00K.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $17.00K.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $24.00K.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for fiscal 2016 was $3.00K.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for fiscal 2014 was $963.00K, a 393.85% increase from fiscal 2013.
- Traws Pharma, Inc. stock issued during period, value, stock options exercised for fiscal 2013 was $195.00K, a 95.85% decline from fiscal 2012.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $24.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $7.00K 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $17.00K 10-Q · filed 2022-05-13 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $3.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | |
| 2014-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28 | $963.00K 10-K · filed 2016-03-28 |
| 2014-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $1.05M derived: sum of 4 quarters · filed 2015-03-30 |
| 2014-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.05M derived: sum of 4 quarters · filed 2015-03-30 |
| 2014-03-31 | $853.00K 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $195.00K 10-K · filed 2015-03-30 |
| 2013-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | |
| 2012-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $4.69M 10-K · filed 2015-03-30 |
| 2012-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | |
| 2011-12-31 | $612.00K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |